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Platelets are small anucleate blood cells derived from megakaryocytes. In addition to their
pivotal roles in hemostasis, platelets are the smallest, yet most abundant, immune cells
and regulate inflammation, immunity, and disease progression. Although platelets lack
DNA, and thus no functional transcriptional activities, they are nonetheless rich sources
of RNAs, possess an intact spliceosome, and are thus capable of synthesizing proteins.
Previously, it was thought that platelet RNAs and translational machinery were remnants
from the megakaryocyte. We now know that the initial description of platelets as “cellular
fragments” is an antiquated notion, as mounting evidence suggests otherwise.Therefore,
it is reasonable to hypothesize that platelet transcription factors are not vestigial remnants
from megakaryocytes, but have important, if only partly understood functions. Proteins play
multiple cellular roles to minimize energy expenditure for maximum cellular function; thus,
the same can be expected for transcription factors. In fact, numerous transcription factors
have non-genomic roles, both in platelets and in nucleated cells. Our lab and others have
discovered the presence and non-genomic roles of transcription factors in platelets, such as
the nuclear factor kappa β (NFκB) family of proteins and peroxisome proliferator-activated
receptor gamma (PPARγ). In addition to numerous roles in regulating platelet activation,
functional transcription factors can be transferred to vascular and immune cells through
platelet microparticles. This method of transcellular delivery of key immune molecules
may be a vital mechanism by which platelet transcription factors regulate inflammation
and immunity. At the very least, platelets are an ideal model cell to dissect out the non-
genomic roles of transcription factors in nucleated cells. There is abundant evidence to
suggest that transcription factors in platelets play key roles in regulating inflammatory and
hemostatic functions.
Keywords: platelets, microparticles, transcription factors, NF-kappa B, PPAR gamma, non-genomic, PPAR alpha,
steroid receptors
INTRODUCTION
Platelets are central players in hemostasis and inflammation, con-
tributing to numerous pathophysiologic conditions (1). They are
unique from the majority of mammalian cells apart from red blood
cells in that they lack a nucleus, and thus have previously been
discounted as “cellular fragments.” This antiquated notion has
been refuted many times over as platelets are now emerging as
cellular mediators of cancer cell metastasis, atherosclerosis, type
II diabetes, and even mediate adaptive immune responses (2, 3).
Platelets are metabolically active cells that contain numerous func-
tional organelles, such as endoplasmic reticulum, Golgi apparatus,
mitochondria, and granules that can be released upon activation.
Although their lack of a nucleus prevents de novo transcription,
they can be activated very rapidly to release copious amounts of
biological mediators within seconds to minutes of stimulation.
The idea that platelets contain transcription factors is a relatively
new concept and has led to the discovery of a large number of
transcription factors in platelets (Table 1). This review will discuss
the newly described roles of transcription factors in platelets, in
addition to proposing uninvestigated potential roles of transcrip-
tion factors in platelets, as extrapolated from findings in nucleated
cells (Table 2).
NUCLEAR FACTOR KAPPA β
In the Immunology field, nuclear factor kappa β (NFκB) is the
most widely recognized transcription factor for its quintessential
roles in regulating inflammation and immune responses. Almost
any immunologist could rattle off key parts of its signaling path-
ways in response to toll-like receptor (TLR) signaling, influenza
infection, or in cytokine production. Although we are quick to
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identify its essential roles in regulating transcription of inflamma-
tory genes, the non-genomic roles of NFκB are often overlooked.
In all fairness, the concept that NFκB has non-genomic roles in
nucleated and non-nucleated cells is a relatively new area of study
that is still in its early stages (4). NFκB signaling molecules regu-
late several different stages of the inflammatory response, without
ever entering the nucleus. For example, the NFκB regulatory pro-
tein, IkappaB kinase β (IKKβ), can alter the function of numerous
proteins via phosphorylation in addition to regulating signaling
through direct interactions with cellular effector molecules (5).
Table 1 | Identified transcription factors in platelets.
Transcription
factor
Activation of
transcription factor
Agonist-induced activation
p65 Phosphorylation ↑ Aggregation, spreading, clot
retraction, GPIBα shedding
PPARγ Ligand binding (15d-PGJ2,
TZDs)
↓ Aggregation, CD40L, TXB2,
P-selectin
Phosphorylation ↑ Collagen-induced activation
and granule secretion
PPARβ/δ Ligand binding
(GW501516, PGI2)
↓ Aggregation
PPARα Ligand binding (fenofibrate) ↓ Aggregation
Phosphorylation ↑ Activation
LXRβ Ligand binding ↓ Collagen-induced
aggregation
RXRα Ligand binding (9cRA) ↓ Activation
GR Ligand binding
(prednisolone)
↓ Activation
Ligand binding
(dexamethasone)
Unknown
AHR Ligand binding ↑ Activation
STAT3 Phosphorylation ↑ Aggregation, P-selectin,
thrombosis
IKAPPAB KINASE IN PLATELETS
Specifically in platelets, the presence and non-genomic functions
of NFκB family members have been demonstrated by several
groups, including our own (6–9). Our group discovered the pres-
ence of the majority of NFκB family members in human platelets,
including the canonical p50/p65 subunits, RelB and c-Rel. Addi-
tionally, we identified the presence of IκB proteins and IKK
members, which regulate NFκB activation (6). Importantly, these
findings suggest that platelets contain an intact, functional, and
complete NFκB pathway. The use of the irreversible inhibitor of
IKKβ phosphorylation, BAY 11-7082 (BAY), has elucidated com-
plex roles for NFκB in platelet signaling. In human platelets, BAY
inhibits platelet spreading and clot retraction, and may alter aggre-
gation at higher doses (6, 10, 11). Malaver et al. (7) and Chen et al.
(12) show that high concentrations of BAY (10–25µM) inhibit
platelet aggregation, while our group saw no effect when platelets
were treated with 0.5–5µM BAY (6). As the IC50 of BAY for inhibi-
tion of IKK-mediated phosphorylation of IκBα is 10µM,<5µM
BAY may be too low to inhibit IKK sufficiently to affect aggregation
(13). Another possibility is that IKK inhibition exerts a threshold
response in affecting platelet aggregation, rather than a dose–
response. Using genetic approaches, Karim et al. demonstrated
that IKKβ knockout mice have variable, but generally attenuated,
aggregation responses to platelet agonists, which may explain some
of the variations observed in human studies as well (14).
Interestingly, the data reported by Chen et al. and Malavar et al.
suggest that the second wave of aggregation was most affected
by IKKβ inhibition, thus affecting the maximum aggregation and
potentiation of the response in human platelets (7, 12). In accor-
dance with this finding, dense granule release was consistently and
potently reduced by IKKβ inhibition in these and other studies.
This finding is likely explained by the ability of IKKβ to phospho-
rylate synaptosomal-associated protein-23 (SNAP-23), an integral
regulator of granule secretion (14). SNAP-23 is a member of the
target sensitive factor attachment protein receptors (SNARE) com-
plex,which interacts with the vesicle-associated membrane protein
(VAMP) to facilitate granule release. IKKβ appears to be central in
enhancing soluble N -ethylmaleimide–SNARE complex formation
Table 2 | Identified and possible interactions of transcription factors in platelets with other proteins.
Transcription factor Known protein interaction Possible protein interactions
Binding partners Outcome Binding partners Outcome
PPARγ Syk, LAT Platelet activation NFκB (p65) Inhibit NFκB activity→ anti-platelet
effect
p-ERK, p-p38 Granule secretion MEK/ERK Increased activation
PKCα Reduce PKCα activation
PPARβ/δ PKCα Dampen platelet adhesion – –
PPARα NFkB Inhibit NFκB activity→ anti-platelet effect PKCα Increased activation
LXRβ Syk, LAT Dampen platelet activation PPARγ Unknown
RXRα PPARγ Unknown Gq Decreased activation
GR HSP90 Unknown – –
Mineralocorticoid Receptor Unknown – –
AHR – – NFκB (p65) Unknown
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though the phosphorylation of SNAP-23. Consequently, platelets
from IKKβ knockout mice have a reduced ability to release alpha,
dense, and lysosomal granules upon thrombin stimulation by
approximately 30%. Likewise, treatment of mouse or human
platelets with an inhibitor of IKKβ similarly reduced granule secre-
tion upon stimulation. These data suggest that the NFκB signaling
molecule, IKKβ, plays an important regulatory role in platelet
activation by transducing critical stimulatory signals.
In general, genetic ablation or pharmacological inhibition of
IKKβ in mice results in a hyporesponsive phenotype to agonist-
induced platelet activation. Inhibition of IKKβ in mice prolonged
thrombus formation and increased bleeding times (14). Addi-
tionally, a second IKKβ inhibitor, IKK inhibitor VII, recapitulated
several of the aforementioned findings in both human and mouse
platelets, including preventing P-selectin expression and damp-
ening aggregation (15). Of note, Gambaryan et al. found that
IKK inhibitor VII potentiated collagen and thrombin-induced
aggregation, rather than having an inhibitory effect (8). They
proposed a model in which thrombin and collagen induce a
negative feedback loop in platelets that inhibits platelet func-
tion through NFκB. Although the work delves into the com-
plex agonist-induced signaling pathways of NFκB in platelets,
their data showing potentiation of platelet activation by IKK
inhibitor VII is less clear-cut. Treatment of human platelets
with IKK inhibitor VII enhanced very low dose (0.001 U/mL)
thrombin-induced PAC1 binding by approximately 15%. Addi-
tionally, IKK inhibitor VII treatment only mildly potentiated
collagen (10µg/mL) and thrombin (0.01 U/mL)-induced platelet
aggregation, with a slight left shift in the aggregation traces com-
pared to control. However, the maximum amplitude of aggrega-
tion was indistinguishable between IKK inhibitor VII treatment
and control. Although the data demonstrating NFκB signaling
post-activation are intriguing, the current consensus is that NFκB
primarily plays an important role in positively regulating platelet
activation.
As much of the investigations into the non-genomic roles of
the transcription factor, NFκB, has involved manipulation of its
upstream regulatory kinase, IKK, careful consideration must be
taken into account when interpreting the findings of these studies.
IKK acts as a kinase that plays a crucial role in regulating NFκB
activation, but can also phosphorylate other proteins that may
play regulatory roles in platelet activation (5). Thus, inhibition of
IKK in platelets may dampen platelet function in a non-canonical
fashion, independent of NFκB. On the other hand, many stud-
ies have observed changes in p65 phosphorylation in platelets,
although the effects of direct inhibition or deletion of p65 has
not been investigated to date. It is likely that IKK activation in
platelets results in NFκB-dependent and -independent regulation
of platelet function. This is supported by the data showing that
IKK phosphorylates SNAP-23 (14), leading to granule secretion,
but can also activate p65, which can regulate protein kinase A
(PKA) (8).
NFκB IN PLATELETS DURING INFLAMMATION
Nuclear factor kappa β in nucleated cells is known to play a
crucial role in inflammatory diseases, although its functions in
platelets during inflammation are still under active investigation.
In one study, IKKβ deficiency increased neointimal formation
in low-density lipoprotein receptor (LDLR) knockout mice and
exhibited increased leukocyte adherence to the vessel walls after
injury (16). Upon further investigation, IKKβ-deficient platelets
were unable to shed GPIbα in response to thrombin stimula-
tion. Interestingly, GPIbα shedding in response to ADP or col-
lagen was not affected, suggesting that IKKβ is uniquely involved
in thrombin-induced GPIbα shedding. These data are intrigu-
ing in light of the fact that many studies evaluating the role
of IKKβ in platelets focused on thrombin-induced activation
and signaling. However, collagen and ADP-induced aggrega-
tion and granule secretion were also dampened by IKKβ defi-
ciency or pharmacological inhibition. Furthermore, no differ-
ences in GPVI, GPIX, or αIIbβ3 shedding were found by loss
of IKKβ in mouse platelets. These data suggest that although
IKKβ plays an important role in the activation of platelets,
it may also induce an inhibitory feedback loop, as proposed
by Gambaryan et al., perhaps through shedding of GPIbα (8).
Sustained levels of GPIbα on the platelet surface can enhance
platelet–leukocyte interactions, and thus, may exacerbate certain
conditions.
Platelets are also known to response to various immunologic
stimuli, such as TLR ligands (17). In nucleated cells, bacter-
ial lipopolysaccharide (LPS) signaling through TLR4 is largely
through NFκB, leading to the production of proinflammatory
cytokines and chemokines. We have recently shown that platelets
can discriminate between different isoforms of LPS (18). This
suggests that platelets are capable of specifically sensing and
responding to various bacterial products. Thus, it is possible that
LPS signaling in platelets involves differential NFkB activation,
although this has not been investigated in platelets to date.
SIGNALING MECHANISM OF NFκB IN PLATELETS
Thrombin activates the NFκB signaling cascade in platelets,
although the complete pathway has not yet been elucidated. Sev-
eral lines of evidence suggest that p38 mitogen-activated protein
kinase (MAPK) signaling is upstream of NFκB in platelets, while
the extracellular signal-regulated kinase (ERK) pathway is down-
stream of NFκB activation (19, 20). In human platelets, inhibition
of MAPK prevented collagen-induced IKKβ and p65 phospho-
rylation, while treatment with an ERK inhibitor had no effect.
Furthermore, collagen-induced ERK phosphorylation was pre-
vented by pretreatment with an MAPK inhibitor or the NFκB
inhibitor BAY, suggesting that NFκB signaling regulates ERK acti-
vation. ERK activates phospholipase A2 (PLA2), which releases
arachidonic acid, leading to platelet aggregation and mediator
release. This explains why arachidonic acid-induced platelet aggre-
gation is unaffected by NFκB inhibitors, while aggregation in
response to other agonists is dampened. Interestingly, one study
suggests that activation of NFκB by CD40L signaling may be inde-
pendent of p38 MAPK, but may instead involve TRAF2 activation
of IKKβ (15). Additionally, protease-activated receptor 4 (PAR4)
stimulation led to ceramide production by sphingomyelin phos-
phodiesterase (Smase), which in turn activated MAPK, while PAR1
signaling was independent of ceramide (12). This is consistent with
the finding that exogenous treatment of platelets with ceramide
leads to in vitro activation and enhances thrombosis in vivo. PAR1
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and PAR4 are the thrombin receptors on human platelets, with
PAR1 having a lower threshold for activation by thrombin than
PAR4 (21). PAR1 activation typically induces a rapid, but transient
spike in calcium, while PAR4 activation involves a more sustained
response, suggesting overlapping, but distinct roles for these recep-
tors (22). These data reveal a novel and distinct signaling pathway
for PAR1 and PAR4 receptors, although both converge on NFκB
signaling.
Taken together, these data present compelling evidence that
NFκB plays an important, albeit complex, role in platelet acti-
vation (Figure 1). The data support a model whereby platelet
activation through various receptors leads to phosphorylation and
activation of IKKβ, release of p65, and subsequent platelet aggre-
gation and granule release. This model, however, is not mutually
exclusive of the idea that NFκB may induce a negative inhibitory
feedback loop in platelets (8). After dissociation of p65 from its
inhibitory complex, PKA is free to induce vasodilator-stimulated
phosphoprotein (VASP) phosphorylation, which mediates platelet
inhibitory signaling. This may represent a mechanism to fine tune
platelet activation after thrombin stimulation. In fact, PIP3 can
induce VASP phosphorylation, leading to inhibitory signaling, in
addition to activating IKK through protein kinase B, also known as
Akt. Thrombin signaling also appears to be unique in that it stim-
ulates GPIb shedding through NFκB and ADAM17, unlike ADP
or collagen-induced activation (16). ADAM17 is a sheddase that is
critical for platelet surface receptor shedding and can be activated
by p38 MAPK (23). Unlike pharmacological inhibition of NFκB
in human platelets, IKK-deficient mouse platelets are unable to
phosphorylate p38 MAPK after thrombin stimulation (16). This
raises the question as to whether defective GPIb shedding in IKKβ-
deficient mouse platelets is an artifact of interspecies variability,
differences in inhibition versus complete lack of IKKβ, or merely
a technical timing issue. Regardless, it will be necessary to inves-
tigate the role of ADAM17 and GPIb shedding in human platelet
NFκB signaling.
NON-GENOMIC FUNCTIONS OF NFκB: LESSONS FROM
NUCLEATED CELLS
Nuclear factor kappa β is a versatile family of proteins capa-
ble of performing multiple functions in nucleated cells apart
FIGURE 1 |The role of NFκB in platelet thrombin signaling.
Thrombin signaling through PAR1 in human platelets is mostly
independent of NFκB. PAR4 signaling in human platelets involves
activation of p38 MAPK through ceramide signaling. Activated p38
MAPK phosphorylates IKKβ, leading to the subsequent ubiquitination
and proteosomal degradation of the inhibitory IκBα protein. Active
p50/p65 dimers activate the ERK signaling cascade, which is involved
in thromboxane TXA2 synthesis and aggregation. The p65 subunit can
also bind PKA, inducing a negative feedback loop through VASP
phosphorylation.
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from acting as a transcription factor (5). Evaluating these iden-
tified non-genomic roles in nucleated cells is likely to translate
to important regulatory functions in platelets. Although roles for
IKKβ in platelets have already been identified, studies from nucle-
ated cells suggest that there may be more. A strong contender
is the role of IKKβ in platelet spreading, as inhibition of IKKβ
in human platelets leads to a spreading defect. In epithelial cells
and B-lymphocytes, IKKβ-mediated phosphorylation of Dok1
inhibits ERK activation, leading to increased cell motility (24).
Platelets are known to transiently activate ERK, which is important
for alpha granule release. However, outside-in integrin signaling
through the fibrinogen receptor, as is likely to occur during platelet
spreading, inhibits ERK signaling (25). Thus, inhibiting IKKβmay
impair platelet spreading through a similar Dok1-mediated mech-
anism. Proteomic data have identified the presence of Dok1 in
human platelets, although its function has yet to be studied in this
context (26).
The NFκB protein p65 and IκBα, are found in the mitochondria
and appear to be differentially regulated compared to their cyto-
plasmic counterparts (27). Interestingly, canonical NFκB stimu-
latory signals had no effect on the expression or phosphorylation
of mitochondria-localized p65 (28). Conversely, stimulation of
liver or Jurkat cells with tumor necrosis factor α (TNFα) or FAS
ligand, respectively, led to non-proteasomal degradation of IκBα
and induction of apoptosis. IKKβ, on the other hand, was not
localized to the mitochondria. To date, most studies of NFκB in
platelets have involved the use of IKKβ inhibitors and IKKβ knock-
out mice. Investigations in platelets centering on the role of IκBα
and p65, in lieu of IKKβ, may reveal novel apoptotic regulatory
elements in platelets.
A second intriguing possibility is the role of 14–3–3β in regu-
lating mRNA stability in platelets. 14–3–3β is a highly conserved
protein that binds AU-rich elements (ARE) on mRNA, leading
to destabilization of mRNA (29). Phosphorylation of 14–3–3β by
IKK results in the release of a 14–3–3β-tritetraprolin complex from
the mRNA, thus preventing its destabilizing effects (30). This is
interesting in light of the fact that platelets contain mRNA, which
can be translated upon stimulation (31) Furthermore, 14–3–3 pro-
teins can interact with p65 and IκBα to facilitate the export of p65
from the nucleus. As proteomic data show that human platelets
express 14–3–3β (32), it is possible that it plays an important role
in regulating mRNA stability or NFκB signaling in the anucleate
platelet.
PPARγ IN PLATELETS
Peroxisome proliferator-activated receptor γ (PPARγ) is a ligand-
activated transcription factor that is important in the regulation
of lipid and glucose metabolism and is essential for fat produc-
tion. Inactive PPARγ is localized to the cytoplasm of nucleated
cells complexed with co-repressors. Upon ligand binding, the
co-repressors dissociate, leading to a conformational change in
PPARγ, allowing dimerization with retinoid X receptor α (RXRα)
(33). This heterodimeric complex then acts as a scaffold for the
recruitment of coactivator proteins, and PPARγ-dependent gene
transcription commences. Our group discovered that human and
mouse platelets express functional PPARγ protein that is regulated
by activation or treatment with PPARγ ligands (34).
PPARγ LIGANDS ARE CARDIOPROTECTIVE
Thiazolidines (TZDs) are a class of oral antidiabetic drugs
that exert their insulin-sensitizing actions through activation of
PPARγ. In addition to regulating glucose homeostasis, TZDs, such
as rosiglitazone, pioglitazone, and troglitazone, have potent anti-
inflammatory properties (35). Type II diabetics taking TZDs have
improved glucose metabolism, decreased markers of inflamma-
tion, and improved cardiovascular health. Much of this can be
attributed to the beneficial actions of TZDs on vascular cells and
both direct and indirect actions on circulating platelets. Platelets
from type II diabetics exhibit a more activated phenotype and
are hyper-responsive to agonist (36, 37). These changes include
increased platelet numbers and mean platelet volume (MPV),
which may indicate alterations in megakaryocyte function or
increased platelet turnover (38). Additionally, platelets from type II
diabetics have enhanced surface expression of the collagen receptor
(GPVI) and the fibrinogen receptor (αIIbβ3), leading to increased
adhesiveness and aggregation (39). Plasma from type II diabetics
contains higher levels of the platelet-derived inflammatory media-
tors, soluble CD40L (sCD40L), soluble P-selectin (sP-selectin), and
C-reactive protein (40, 41). Dsyregulated platelet function in type
II diabetics is likely due to both inherent changes in the platelet
and decreased prostaglandin I2 (PGI2) and nitric oxide (NO) pro-
duction from endothelial cells, which exert potent anti-platelet
effects.
Numerous studies have demonstrated that TZDs beneficially
regulate cardiovascular function in type II diabetics. They have
consistently been shown to reduce the elevated levels of plasmino-
gen activator inhibitor 1 (PAI-1) (42–44). PAI-1 rapidly binds and
inactivates tissue plasminogen activator, thus preventing fibrinol-
ysis and increasing thrombotic risk. Additionally, TZDs reduce
markers of cardiovascular disease, which are typically elevated in
type II diabetics, including C-reactive protein, serum amyloid A,
fibrinogen, and matrix metalloproteinase 9 (45–49). Many of these
beneficial changes can be attributed to improved glucose metabo-
lism and restored vascular and endothelial homeostasis, although
similar results can be seen in non-diabetic patients (50).
PPARγ LIGANDS IMPROVE PLATELET FUNCTION IN TYPE II
DIABETIC
Consistent with their ability to reduce thrombotic risk, TZDs
reduce markers of platelet activation. Rosiglitazone monotherapy
decreased plasma sCD40L and P-selectin levels (51, 52). These data
suggest that TZDs can directly or indirectly reduce platelet acti-
vation in type II diabetics. Supporting these findings, Khanolkar
et al. demonstrated that patients receiving rosiglitazone and met-
formin had a significantly greater reduction in platelet aggregation
compared to patients receiving gliclazide and metformin (53).
Similarly, a second study found that pioglitazone in combination
with metformin improved platelet function to a greater degree
than glimepriride and metformin (49). A major unanswered ques-
tion from these studies is whether TZDs improve cardiovascular
health secondary to improved lipid metabolism or due to the
anti-inflammatory actions of PPARγ stimulation. For example,
macrophages, which play a key role in atherosclerosis, efflux cho-
lesterol and are less inflammatory in response to PPARγ activation.
In an attempt to investigate the insulin-sensitizing independent
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effects of TZDs, non-diabetic patients with coronary artery disease
were treated with TZDs for 12 weeks. In this setting, TZDs reduced
the inflammatory markers, C-reactive protein, tumor necrosis fac-
tor α (TNFα), and interleukin-6 (IL-6) (50, 54). Additionally,
circulating platelet activity was dampened, as evidenced by fewer
P-selectin positive platelets, suggesting an important role for the
anti-inflammatory actions of PPARγ.
PPARγ LIGANDS DAMPEN PLATELET FUNCTION FROM
HEALTHY DONORS
Due to the global effects of TZDs, it is difficult to tease out indirect
actions from potential direct effects of TZDs on platelet func-
tion. However, many recent studies have aimed to elucidate the
direct effects of TZDs on platelet function. Our lab was the first
to show that human platelets and megakaryocytes express func-
tional PPARγ (55). The PPARγ ligands 15d-PGJ2 and rosiglitazone
potently inhibit thrombin-induced CD40L surface expression and
thomboxane B2 (TXB2) production and dampen ADP-induced
aggregation (56). Other studies have confirmed these findings and
further demonstrated that rosiglitazone and 15d-PGJ2 inhibited
collagen-induced aggregation and prevented P-selectin exposure
in vitro and in vivo (54, 57). Utilizing the specific PPARγ antag-
onist, GW9662, these effects were partially mediated through
PPARγ in platelets from healthy donors (58). Moreover, piogli-
tazone was protective in a mouse model of thrombosis (57, 59).
Similarly, using platelets from type II diabetics, which are hyper-
responsive to agonist, rosiglitazone reduced aggregation and medi-
ator release (36, 60). These data support the hypothesis that TZDs
can regulate platelet function by directly acting on platelet PPARγ.
Interestingly, PPAR-independent pathways are evident upon
treatment with some ligands. 15d-PGJ2 is an electrophilic com-
pound that is known to form adducts with other cellular proteins,
and could explain some of the PPAR-independent effects (61).
Most interestingly, the mechanism of troglitazone differs from that
of the structurally similar TZD, pioglitazone, in platelets. Although
troglitazone and pioglitazone decreased platelet activation in vivo,
only troglitazone directly inhibited platelet aggregation in vitro
(62). However, in this study, only 1µM of each TZD was examined
for their effects on platelet function. In some cell systems, trogli-
tazone is more potent than pioglitazone, despite having a higher
EC50 for binding PPARγ and this may also be the case in platelets
(63). It is possible that higher concentrations of pioglitazone
would exhibit similar effects as troglitazone. Another possibil-
ity is that there may be PPAR-independent effects or differential
signaling of PPARγ in human platelets. Clinical data points to
some PPAR-independent actions of TZDs as pioglitazone has been
shown to decrease the risk of myocardial infarction and stroke in
type II diabetics, while rosiglitazone had no effect and may actually
increase the relative risk (64).
SIGNALING MECHANISM OF PPARγ IN PLATELETS
Differential signaling of PPARγ is not an unprecedented finding,
as PPARγ is known to recruit various co-activators after stimu-
lation with different ligands. Although most TZDs bind identical
binding pockets in PPARγ, their biological profiles are distinct (65,
66). This is in part due to differential recruitment of co-activators,
but also possibly due to variations in availability of cofactors. In
cell-based systems, PPARγ ligands can act as partial agonists in
some cell types and full agonists in others (67). Additionally, dif-
ferent PPARγ ligands can recruit different co-activators in the same
cell type, leading to different outcomes (68–70). These differences
likely explain many of the adverse effects observed with some TZDs
in clinical trials. Although still poorly understood, differential
binding and recruitment of cofactors may explain the complex and
sometimes contradictory actions of PPARγ in platelets, although
no studies have evaluated this role of PPARγ in platelets to date.
Although a transcription factor, PPARγ has been shown to
serve many other important non-genomic roles in platelets and
nucleated cells (Figure 2). Specifically in platelets, collagen stim-
ulation results in PPARγ recruitment to the GPVI signalosome
and interacts with the adapter molecule, Syk (71). As a result,
linker of activated T cells (LAT) is recruited and forms a com-
plex with Syk and PPARγ. In this setting, PPARγ appears to
be necessary for enhancement of GPVI-mediated activation as
treatment with PPARγ antagonists only partially blocks phos-
phorylation of LAT and the downstream targets phospholipase
Cγ (PLCγ), PI3K, and Akt. Interestingly, several other groups
have demonstrated that cytosolic platelet PPARγ is released into
the supernatants and in platelet-derived microparticles rapidly
upon activation, leaving very low levels of PPARγ in the acti-
vated platelets (34, 72). This may suggest that early signaling
FIGURE 2 |The role of PPARγ in collagen signaling in platelets. GPVI
stimulation with collagen leads to the recruitment and activation of Syk. Syk
recruits and phosphorylates PPARγ, which in turn leads to the recruitment
of LAT, resulting in enhanced signal transduction downstream of GPVI.
PPARγ ligands prevent the interaction of PPARγ with the Syk signaling
complex, which is necessary for enhanced signaling of Syk and LAT.
Ligand-bound PPARγ can also interact with PKCα, preventing it from
mediating dense granule release. Lastly, ligand-activated PPARγ prevents
PPARγ phosphorylation and interaction with MAPK, an essential
downstream mediator of collagen signaling.
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roles of PPARγ include recruitment to the LAT/Syk signal-
ing complex, which results in its packaging and export into
microparticles, possibly due to its proximity to the cell mem-
brane. Alternatively, there may be different pools of PPARγ
that could have different subcellular localization patterns. It is
not known whether platelets contain an unknown endogenous
PPARγ ligand that plays a role in this signaling pathway. How-
ever, exogenous treatment of activated platelets with PPARγ
ligands inhibit its interaction with the LAT/Syk signaling com-
plex and reduces the amplitude of the signal, thus reducing
aggregation and mediator release. Similarly, PPARγ ligands also
blunt release of PPARγ into the supernatants and platelet-derived
microparticles (34).
Separate studies have suggested that PPARγ interacts with ERK
and p38 MAPK, which are common downstream mediators of
platelet activation, leading to granule secretion (73). Stimulation
of human platelets with collagen led to phosphorylation of PPARγ
and its subsequent association with p-ERK and p38 MAPK. Treat-
ment with PPARγ ligands prevented these interactions, reducing
granule release. Similarly, PPARγ has been shown to interact with
PKCα in platelets in response to PPAR agonists, consequently
reducing the activation of PKCα (74). Although complex, there
is sufficient evidence to suggest that PPARγ plays an important
role in platelet signaling. PPARγ knockout mice are embryonic
lethal; thus, a megakaryocyte and platelet-specific PPARγ knock-
out mouse model would be invaluable in determining the biologic
role of PPARγ in platelets. As platelets do not contain a nucleus,
any genomic deletion of PPARγ in platelets must also be deleted
in the parent megakaryocyte. Therefore, changes in platelet func-
tion in these mice could be due to the loss of PPARγ in the
platelet or megakaryocyte. Our group has recently shown that
overexpression of PPARγ in a megakaryocyte cell line resulted in
enhanced platelet production upon stimulation with a PPARγ lig-
and (72). These data suggest that PPARγ may play an important
role in platelet production from megakaryocytes and could poten-
tially convolute findings from megakaryocyte and platelet-specific
PPARγ knockout mice.
PPARβ/δ
PPARβ/δ is broadly expressed and plays an important role in skele-
tal muscle where it regulates cellular proliferation, differentiation,
and fatty acid catabolism (75). Similar to PPARγ, PPARβ/δ is
found in human and mouse platelets and PPARβ/δ ligands inhibit
platelet function (76). Treatment with the specific PPARβ/δ lig-
and, GW501516, significantly increased cAMP levels in mouse
platelets and prevented aggregation (77). Utilizing platelets from
PPARβ/δ knockout mice, the increase in cAMP was shown to
be specific to PPARβ/δ signaling, as cAMP levels in knockout
platelets were drastically lower in response to ligand. Interestingly,
no difference in aggregation was observed between knockout and
control platelets treated with GW501516, suggesting that the inhi-
bition of platelet aggregation by GW501516 occurs independent
of PPARβ/δ. Furthermore, no differences were observed between
knockout and control platelets’ ability to produce cAMP or aggre-
gate in response to ADP in the absence of PPARβ/δ ligand. This
indicates that PPARβ/δ in platelets may require ligand binding to
exert its inhibitory effects on platelet function. Nevertheless, these
data demonstrate that PPARβ/δ is capable of signaling in platelets,
although the physiologic relevance remains unclear at this point.
One possible mechanism by which PPARβ/δ dampens platelet
activation may involve the endogenous antithrombotic molecule,
prostacyclin I2 (PGI2). PGI2 is produced by endothelial cells and
is reported to be a ligand for PPARβ/δ (78), although this has
not been proven in platelets. Previous studies have shown that
PGI2 can synergize with endothelial-derived NO to inhibit platelet
aggregation in response to variety of agonists through a mecha-
nism involving increased cAMP (76). Another possible mechanism
of action of PPARβ/δ in platelets may involve modulation of PKCα
function. Treatment of human platelets with GW501516 induced
association of PPARβ/δ with PKCα in a dose-dependent manner
(77). PKCαhas been shown to positively regulate platelet adhesion,
a function that was dampened with PPARβ/δ activation. Overall,
very little is known about the biological significance and mecha-
nism of PPARβ/δ in platelets, although the available data suggest
a role in inhibiting platelet activation.
PPARα
PPARα is a major regulator of fatty acid homeostasis and inflam-
mation. It is highly expressed in brown adipose tissue, liver, kidney,
heart, and skeletal muscle (75). PPARα agonists are used as a
treatment for elevated plasma lipid levels and for their ability to
increase the uptake of fatty acids and improve the high-density
lipoprotein (HDL) to low-density lipoprotein (LDL) ratio. Little
is known about the function of PPARα in regulating hemosta-
sis, but its presence was recently discovered in platelets. Statins
and fibrates are PPARα agonists and are widely prescribed for the
prevention of coronary artery disease and atherosclerosis, thus
reducing the risk of thrombotic events (74). In addition to their
effects on lipid metabolism, statins and fibrates have been shown
to activate PPARα (79). Specifically, fenofibrate decreased agonist-
induced platelet activation and increased bleeding times in mice
(74). Fenofibrate’s ability to inhibit platelet aggregation was abol-
ished in the presence of a specific PPARα antagonist. Additionally,
bleeding times in PPARα knockout mice were not affected by
treatment with fenofibrate, unlike control mice. Interestingly, the
baseline bleeding times in PPARα knockout mice were longer than
control mice, suggesting an additional role for PPARα in maintain-
ing hemostasis. Due to the usage of PPARα global knockout mice,
it is unclear whether this difference was due to platelet-specific or
multivariate effects. Although the mechanisms of action of PPARα
in platelets have not been thoroughly investigated, some evidence
suggests that it may regulate PKCα activity, similar to PPARγ and
PPARβ/δ (80).
NON-GENOMIC FUNCTIONS OF PPARs: LESSONS FROM
NUCLEATED CELLS
The wide use of PPAR ligands in the clinic has led to the
discovery of numerous pleotropic effects of these compounds.
These include PPAR-dependent, non-genomic actions in addition
to PPAR-independent signaling of ligands (81, 82). The PPAR-
independent signaling mechanisms of PPAR ligands will not be
discussed here, but these effects must be kept in mind when inter-
preting data investigating the effects of PPAR ligands on platelet
function. In fact, these likely play an important role in regulating
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platelet function, perhaps through affecting mitochondrial activ-
ity, as many effects of PPAR ligands in platelets cannot be reversed
using PPAR antagonists. Additionally, many PPAR ligands, such as
unsaturated fatty acids, can cross-react with all PPAR isoforms at
higher concentrations, further complicating the interpretation of
these findings (83). It may be possible to generate useful hypothe-
ses about how PPARs signal in platelets based upon similar studies
in nucleated cells.
PPARγ–PKCα CROSSTALK
In human epithelial colorectal adenocarcinoma cells, PPARγ has
been shown to regulate NFκB activity in a non-genomic fash-
ion involving their direct association (84). In this model, PPARγ
bound to p65 in the nucleus, resulting in export of both proteins
to the cytoplasm. Consequently, cytoplasmic localization of NFκB
prevented its proinflammatory transcription-dependent effects. It
is possible that PPARγ can also physically interact with p65 in
platelets. This interaction could inhibit NFκB activity in platelets,
which would exert anti-inflammatory and anti-platelet effects.
PPARγhas also been shown to form a direct interaction with PKCα
upon stimulation with various PPARγ ligands in macrophages
(85). The physical association of PKCα with PPARγ prevented
PKCα translocation to the membrane and subsequent degrada-
tion. However, in this system PPARγ was only able to negatively
regulate PKCα activation in response to low-dose PMA stimu-
lation. This suggests that the inhibitory effect of PPARγ can be
overridden with stronger stimulation.
PPARα–PKCα CROSSTALK
Interestingly, PPARα has also been shown to directly interact with
PKCα in macrophages (86). In response to LPS stimulation, PKCα
bound and phosphorylated PPARα. However, in the presence of
the PPARα ligand, simvastatin, PPARα no longer bound PKCα
and consequently was able to transrepress NFκB activation. In
this model, PKCα likely acts to deactivate PPARα’s inhibitory
actions on the proinflammatory NFκB signaling. This may rep-
resent a mechanism by which PPARα ligands, such as statins, exert
potent and rapid anti-inflammatory actions. Although the inter-
action of PPARα with PKCα was postulated to negatively regulate
PPARα’s function in this system, it is possible that this complex
serves additional and possibly proinflammatory functions. Simi-
larly, these data suggest that in platelets, ligand-induced activation
of PPARαmay function differently than phosphorylation-induced
activation, resulting in different or possibly contradictory actions.
This may even explain the discrepancy between the bleeding phe-
notype observed in PPARα knockout mice, while control mice
also had increased bleeding times with PPARα activation. Per-
haps, PPARα, independent of ligand, acts as a positive regulator
of platelet hemostatic function by enhancing activation of PKCα,
while ligand-activated PPARα sequesters and inhibits NFκB thus,
negatively regulating platelet activation (Figure 3).
PPARγ AND PPARα REGULATE MAP KINASES
Another possible role of PPARα in platelets involves regulation of
MAP kinases. In T cells, PPARα was shown to inhibit p38 MAPK
FIGURE 3 | Possible mechanism of PPARα and NFκB regulation in
platelets. Platelet activation leads to NFκB phosphorylation and activation,
which potentiates activation signals. PKCα is also phosphorylated and
activated in response to stimulation. This may lead to an interaction between
PPARα and PKCα, leading to increased activation. Treatment with PPARα
ligands prevents PPARα binding to PKCα, but instead enhances its interaction
with NFκB, thus functionally sequestering PPARα and NFκB from participating
in activation signaling.
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activation, but only in the absence of ligand (87). Additionally, this
regulation of p38 MAPK appeared to be independent of direct
interaction with PPARα, but likely required an unknown sec-
ondary mediator. Activation of p38 MAPK occurs early in platelet
activation, albeit transiently, to induce granule release that stimu-
lates the second wave of aggregation (88, 89). Subsequent ligand
binding to αIIbβ3 downregulates active p38 MAPK (90). Perhaps,
PPARα mediates the regulation of p38 MAPK in these condi-
tions or possibly under shear stress, whereby p38 MAPK mediates
adhesion in flow.
PPARγ has also been shown to regulate MAPK pathways in
nucleated cells through non-genomic mechanisms (91). PPARγ
reversibly interacts with MEK1 via its AF2 domain, resulting in
export from the nucleus to the cytoplasm. This corroborates evi-
dence suggesting that PPARγ ligands regulate downstream ERK
signaling (92). Interestingly, PPARγ activation led to rapid ERK
phosphorylation in human prostate cancer cells, vascular smooth
muscle cells, and human microvascular endothelial cells, but
inhibited ERK activation in adrenocortical cancer cells (93–95).
Similarly, PPARγ enhanced ERK activation in rabbit renal cortex
cells, but had no effect in mouse cells (96). These data suggest
cell type-specific and species-specific effects of PPARγ, possi-
bly through availability of different co-activators. The effects of
PAPRγ activation on the MEK/ERK pathway in platelets has not
been investigated, but represents a promising avenue of further
research.
LIVER X RECEPTORS
Liver X receptors (LXRs) are transcription factors that play
key roles in cholesterol homeostasis by regulating genes, such
as apolipoprotein E and cytochrome P450 7α-hydroxylase 1
(Cyp7a1) (97, 98). Recent studies have demonstrated that platelets
express LXRβ and its ligands inhibited collagen-induced aggre-
gation (99). Thrombin and fibrinogen-induced activation was
affected to a lesser degree, requiring high doses of LXR ligands to
exert comparable inhibitory effects. Collagen-induced Syk phos-
phorylation was strongly inhibited by pretreatment with LXR
ligands, while LAT and PLCγ phosphorylation were inhibited to
a lesser degree, which could be explained by the high concentra-
tion of collagen used for activation (50µg/mL). Interestingly, and
opposite of the results seen with PPARγ (71), LXR ligands induced
association of LXR with Syk and PLCγ. Moreover, stimulation of
platelets with PPARγ or LXR ligands led to an association between
the two transcription factors, which was diminished with higher
concentrations of ligand. Taken together, these data suggest that
LXR and PPARγ can physically interact in platelets and this may
represent a novel regulatory mechanism of collagen-induced acti-
vation (Figure 4). In cell free systems, LXRβ was able to bind all
three PPAR isoforms with different affinities (100). Moreover, dif-
ferent PPAR ligands altered the affinities of these interactions. For
example, troglitazone inhibited PPARγ/LXRβ interactions, while
GI262570, a PPARγ ligand with high binding affinity, had no
effect on this interaction. This may help to explain why different
FIGURE 4 | Regulation of collagen signaling by LXRβ and PPARγ. Collagen
signaling leads to the phosphorylation of Syk and PPARγ. Ligand-activated
LXR binds Syk, preventing its interaction with PPARγ, thus decreasing platelet
activation. Similarly, PPARγ ligands or LXR ligands can induce the interaction
of PPARγ and LXR, reducing the availability of PAPRγ to participate in collagen
signaling.
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PPAR ligands exert different effects on platelet signaling and
function.
RETINOID X RECEPTORS
Retinoid X receptors comprise a group of nuclear receptors that
recognize vitamin A metabolites (101). The three different iso-
forms of RXRs (α, β, and γ) are expressed in different tissues,
with RXRα and RXRβ being fairly widely expressed and RXRγ
is mainly expressed in skeletal muscle and heart tissue (102).
RXRα is the heterodimeric binding partner of PPARγ, which is
essential for mediating the genomic effects of PPARγ. Platelets
express the RXRα and β isoforms, but not RXRγ, and RXRs
immunoprecipitate with PPARγ in platelets. (103) Similar to
PPARγ ligands, the RXR ligand, 9-cis-retinoic acid (9cRA), inhib-
ited agonist-induced platelet activation. Interestingly, however,
9cRA preferentially inhibited ADP and U46619 (a thromboxane
mimetic)-induced aggregation, but did not alter collagen-induced
activation. This is surprising in light of the fact that PPARγ lig-
ands dampen signaling through the collagen receptor (Figure 2),
suggesting that RXR in platelets can signal non-genomically inde-
pendent of PPARγ. RXRα co-immunoprecipitated with Gq11 in
resting platelets and this interaction was enhanced when platelets
were stimulated with 9cRA. In this manner, ligand-bound RXRα
may sequester Gq from its traditional role in propagating sig-
nals from G-protein coupled receptors, such as the ADP and
thromboxane receptors.
GLUCOCORTICOID RECEPTORS
The glucocorticoid receptor (GR) is a nuclear hormone recep-
tor that binds glucocorticoids, such as dexamethasone and
prednisolone, resulting in an anti-inflammatory response (104).
Human platelets express GR and differentially respond to its
ligands (105). One study found that human platelets were less
responsive to activation when treated with prednisolone, but not
dexamethasone (106). Furthermore, the inhibitory effects of pred-
nisolone on platelet function could be prevented by treatment
with the GR antagonist, RU486. Interestingly, binding assays in
human platelets revealed that both glucocorticoids could bind GR
and increase its association with the chaperone protein, HSP90.
In nucleated cells, ligand binding to GR causes HSP90 dissocia-
tion from the GR complex, which reveals its nuclear localization
signal (107). However, the opposite effect was found in platelets,
suggesting a different method of regulation. Moreover, a unique
dimerization was identified in human platelets between GR and
the mineralocorticoid receptor (MR), which can bind some of the
same ligands as GR, such as dexamethasone. This may help to
explain why dexamethasone affected platelet function differently
from the more specific GR agonist, prednisolone. Additionally,
mineralocorticoids activate PI3K, consistent with the finding that
mineralocorticoid actions are associated with increased risk of
vascular disease (108).
ARYL HYDROCARBON RECEPTOR
The aryl hydrocarbon receptor (AHR) is a well-known toxicant-
sensing receptor that also plays essential roles in immune func-
tion and hematopoiesis (109). Common AHR ligands include
polycyclic aromatic hydrocarbons, lipoxin A4, and 2,3,7,8-
tetrachlorodibenzo-p-dioxin (TCDD). Mouse platelets express
AHR, which is known to play an important role in hematopoiesis
and megakaryocyte development (110). Platelets from AHR
knockout mice exhibit defective collagen signaling, with inhib-
ited collagen-induced aggregation and spreading. Of note,platelets
from AHR knockout mice had lower levels of the collagen receptor,
GPVI, and undetectable levels of Vav proteins. Vav1 and Vav3 are
activated downstream of many signaling pathways in platelets, and
play a role in responding to collagen (111). Although the defects in
platelet collagen signaling in AHR knockout mice are intriguing
and may suggest an important role for this transcription factor
in platelet biology, a more thorough investigation is needed. It
is still unknown whether platelets respond to AHR ligands and
whether they affect agonist-induced activation. Moreover, it is pos-
sible that the defects in collagen signaling in AHR knockout mice
could be solely attributed to defective thrombopoiesis and altered
platelet composition. Limited studies have evaluated the effects
of AHR ligands in hemostasis. Polychlorinated biphenyls, which
are non-specific AHR ligands, enhanced human platelet activation
(112). Additionally, the specific AHR ligand, TCDD, was shown
to induce thrombocyte aggregation in zebrafish (113). This can
likely be attributed to its non-genomic actions in thrombocytes,
as these effects were seen as early as 30 min post-treatment. Fur-
ther research investigating the effects of AHR activation in platelets
may reveal novel actions of environmental toxicants on hemostasis
and cardiovascular risk.
The AHR has been shown to form a complex with the p65
subunit of NFκB in breast cancer cells (114). Furthermore, this
interaction was found to be functionally relevant, resulting in
proliferation and tumorigenesis. Additional roles for the AHR in
regulation of NFκB signaling have been shown by our group in
fibroblasts (115, 116). We found that absence of the AHR coincided
with decreased expression of the non-canonical NFκB member,
RelB. Signal-specific phosphorylation of RelB targets it for proteo-
somal degradation. It is possible that physical association between
the AHR and RelB prevents its proteosomal degradation and allows
it to exert anti-inflammatory effects, similar to its regulation in T
cells (117).
SIGNAL TRANSDUCER AND ACTIVATOR OF
TRANSCRIPTIONS
The signal transducer and activator of transcription (STAT) family
of proteins were some of the first identified functional transcrip-
tion factors in platelets (118). Human platelets express STATs 1, 3,
and 5, which traditionally play a role in transducing signals from
cytokine receptors to elicit an immune response (119). Early on,
it was known that thrombopoietin could act on human platelets
and this resulted in STAT3 phosphorylation, although the bio-
logical significance was unclear. Recently, the role of STAT3 in
platelet signaling has been investigated more thoroughly, uncov-
ering an important role for it in GPVI signaling (120). Pharmaco-
logic inhibition of STAT3 signaling or dimerization resulted in a
hyporesponsive phenotype to low-dose collagen activation. Addi-
tionally, platelets from platelet and megakaryocyte-specific STAT3
knockout mice had lower levels of collagen-induced aggregation,
decreased P-selectin expression, and slowed thrombus formation.
Interrogation of the signaling cascade revealed that STAT3 was
activated by JAK2, in the same manner as in nucleated cells.
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Traditionally, STAT3 homodimerizes upon phosphorylation by
JAK2, then translocates to the nucleus where it acts as a tradi-
tional transcription factor. However, in platelets, phosphorylation
of STAT3 by JAK2 resulted in dimerization and activation of PLCγ.
Syk was found to be an upstream activator of this pathway and
was complexed with STAT3 and PLCγ after activation with col-
lagen (121). These data suggest that STAT3 plays an important
regulatory role in platelet activation downstream of collagen and
thrombopoietin signaling.
THE DIVERGENT ROLES OF TRANSCRIPTION FACTORS
The investigation of transcription factors in platelets has often
led to convoluted and sometimes contradictory findings. This can
most clearly been seen in the evaluation of the roles of PPARα
in platelets. In this case, PPARα appears to play an important
role in platelet activation, but has the opposite effect in the pres-
ence of a PPARα ligand (74). Additionally, phosphorylated PPARγ
positively regulates collagen signaling, while ligand-bound PPARγ
inhibits activation (71). These data support the hypothesis that
ligand-induced activation of transcription factors can function
differently than phosphorylation-induced activation (Figure 3).
MICROPARTICLES AS TRANSPORTS OF TRANSCRIPTION
FACTORS
Microparticles are plasma membrane-derived vesicles ranging
in diameter from 0.1 to 1µm that are present at levels of
approximately 5–50µg/mL in blood plasma (122). Platelets and
megakaryocytes are the primary source of microparticles in the
blood circulation (about 80%), whereas other microparticles are
derived from erythrocytes, endothelial cells, and granulocytes
(122–124). Since their discovery, the role of platelet microparticles
in coagulation was evident, and later was supported by identifica-
tion of tissue factor expression (123) and a phosphatidylserine-
rich outer membrane (125) that binds coagulation factors to
aid in their assembly and enzymatic processing. Microparticles
are produced from resting cells, during apoptosis or during cell
activation, likely resulting in different internal and surface com-
position. Microparticles were shown to differ in composition
between human samples and between microparticle size classes
(126, 127). Packaging mechanisms for microparticles have not yet
been identified and such studies are crucial for the understand-
ing of microparticle influences on their environment. Whether
microparticle packaging is a passive or active process, increased
proximity of mediators to the cell plasma membrane would likely
increase their chances of becoming encapsulated by the released
microparticles.
MICROPARTICLE FUNCTIONS AND ROLES IN
INFLAMMATION
Microparticles are postulated to have several means to influ-
ence their environment. Burger et al. described their ability to
(1) promote coagulation, (2) scavenge NO, (3) generate reactive
oxygen species, (4) cleave cellular surface proteins via metallopro-
teinases, (5) signal cells via surface proteins, and (6) deliver cargo
via transfer of membrane and internal contents (128). Addition-
ally, microparticles are postulated to contribute to, and sometimes
exacerbate inflammation. It is likely that surface interactions and
the less studied delivery of internal microparticle contents are
both contributing to the influences of microparticles on their
environment.
TRANSCELLULAR COMMUNICATION
Circulating microparticles can interact with other blood cells they
encounter, such as leukocytes, lymphocytes, platelets, and with
endothelial cells. Specific modes of cell–microparticle interac-
tions include surface receptor signaling, plasma membrane fusion,
or internalization of microparticles (129). The fusion of platelet
microparticle membranes to target cell membranes was demon-
strated to transfer the surface protein CXCR4 to cells causing
recipient cell susceptibility to human immunodeficiency virus
infection (130). Membrane fusion or internalization of micropar-
ticles could also cause microparticle internal composition to be
transferred into the recipient cell cytoplasm. Lipids (131), RNA,
and protein (129) have been seen to be delivered in this fashion,
and multiple examples of each are reviewed by Mause and Weber
(132). Arachidonic acid is a lipid mediator delivered by platelet
microparticles that can be further processed into thromboxane
A2 by recipient platelets and contribute to their activation (131).
Overall, platelet microparticles contain various mediators that can
be delivered to surrounding cells to impact their function.
TRANSCRIPTION FACTORS IN MICROPARTICLES AND ROLES
IN TRANSCELLULAR COMMUNICATION
The influence of microparticles on recipient cell function is based
on microparticle composition. Not surprisingly, blood micropar-
ticle protein composition was found to be highly variable between
healthy humans (127). Our work showed that platelet microparti-
cles contain transcription factors, such as PPARγ, derived from
parent cells (34). Furthermore, proteomic analysis has led to
the discovery of three other transcription factors in platelet
microparticles, RuvB-like 2, STAT3, and STAT5A (133).
Transcription factors are transported from cells through
microparticles and retain function within the recipient cells (34,
72). Our lab was the first to show this ability with platelet-derived
microparticles delivering functional PPARγ to THP-1 monocytes,
detected through an electrophoresis mobility gel shift assay (134).
We have since developed a novel platform technology to engineer
microparticles through overexpression of PPARγ in platelet and
megakaryocyte-derived microparticles obtained from the cultured
megakaryoblastic cell line, Meg-01 cells. We showed that these
engineered microparticles could be taken up by THP-1 monocytes,
and that the transferred PPARγ was functional within recipi-
ents shown by induction fatty acid binding protein-4 (FABP4)
expression, a unique PPARγ-specific target gene (72) (Figure 5).
To identify the significance of the transferred PPARγ to recip-
ient cells, we compared recipient cell responses incubated with
microparticles that did or did not contain PPARγ, to inflamma-
tory stimuli (135). Monocytes that received PPARγ-containing
microparticles had decreased inflammatory mediator production
compared to the control microparticles. PPARγ activation has
been shown to induce cell differentiation (136, 137). Our work also
supported the influence of PPARγ on monocyte differentiation as
the cells receiving PPARγ-containing microparticles became more
adherent through increased integrin expression and fibronectin
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FIGURE 5 | Platelet microparticles as a method of transcellular
delivery of transcription factors. Platelet-derived PPARγ is packaged
into platelet microparticles, which can deliver intact PPARγ protein to
target cells, such as monocytes. PPARγ can then bind to peroxisome
proliferator response elements (PPRE) in the nucleus to affect
transcription of target genes. Transfer of PPARγ to monocytes via
microparticles has been shown to decrease LPS-induced inflammatory
mediator release.
production (135). These data support the notion that circulating
microparticles could have a profound impact on inflammatory
cells during responses to insult and injury. Specifically, the anti-
inflammatory PPARγ and proinflammatory NF-κB composition
of microparticles could vastly dampen or heighten responses of
recipient cells.
DIAGNOSTIC AND THERAPEUTIC POTENTIAL OF
MICROPARTICLES
Measurements of microparticle abundance are becoming a more
popular assessment of systemic inflammation. With current tech-
nology, it is easier and less expensive to measure micropar-
ticle number and surface composition rather than running
entire microparticle proteomic studies with each patient sam-
ple. Microparticle number and surface phenotype have provided
descriptive diagnostic tools indicative of disease severity. How-
ever, evaluation of the total protein composition of microparticles
would tell an infinitely more detailed summary of patient health
status. Particularly, looking at levels of the highly influential tran-
scription factors within circulating microparticles would provide
insight into the inflammatory state from the cells generating the
microparticles as well as the potential inflammatory impact on
recipient cells within the blood.
Delivery of platelet proteins such as PPARγ could have an anti-
inflammatory and/or pro-differentiation influence on activated
cells via microparticles and act as a physiological means of quench-
ing inflammation. Transcription factors would be among the most
influential mediators to deliver to a cell, as they are capable of
initiating transcripts of multiple downstream products that could
influence numerous networks and pathways. Certain transcription
factors may require signal or ligand activation to fully function in
a microparticle delivery setting. In the case of PPARγ, endogenous
ligands such as 15d-PGJ2 and others may be present or synthe-
sized. Whereas the components delivered by microparticles may
be short-lived, their effects on the recipient cells may sometimes be
permanent, such as inducing irreversible differentiation or death
of recipient cells.
Overall, platelet microparticles are abundant and influential
transcellular vesicles. They contain proteins, lipids, and RNA
derived from their parent cells. Therefore, these circulating bio-
markers provide insight into the cumulative activation and inflam-
matory state of all blood cell populations. Importantly,microparti-
cles have repeatedly been shown to not just be cell byproducts but
rather influential delivery mechanisms. Transportation of tran-
scription factors to cells could influence several ongoing or initiate
new pathways causing profound impacts within recipient cells.
Transcellular communication involving transcription factors via
platelet microparticles substantiates another possible key role of
transcription factors presence in platelets.
CONCLUSION
Transcription factors play numerous important and previously
unrecognized roles in regulating platelet function in a non-
genomic manner. Additionally, transfer of intact and functional
transcription factors to other cells via microparticles may serve
as a novel regulatory mechanism for inflammation. The initial
discovery of transcriptional regulatory elements in a particular
protein does not exclude the possibility of non-genomic roles
for that protein as well. The anucleate platelet can serve as an
important model system to study non-genomic roles of tran-
scription factors. Further elucidation of the non-genomic func-
tions of transcription factors will yield important discoveries that
have the potential to illuminate platelet biology and also help to
explain the pleotropic effects of pharmaceuticals that target these
pathways.
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